Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -3,415.81%.

  • Mereo BioPharma Group's EBITDA Margin fell 563309.00% to -3,415.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,478.50%, marking a year-over-year increase of 59401183.00%. This contributed to the annual value of 3,256.72% for FY2024, which is 350936.00% up from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's EBITDA Margin is -3,415.81%, which was down 110.29% from 33,204.17% recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's EBITDA Margin ranged from a high of 33,204.17% in Q2 2025 and a low of -3,415.81% during Q3 2025.
  • In the last 3 years, Mereo BioPharma Group's EBITDA Margin had a median value of 2,217.28% in 2024 and averaged 4,558.40%.
  • Over the last 5 years, Mereo BioPharma Group's EBITDA Margin had its largest YoY gain of 2,950,326bps in 2025, and its largest YoY loss of 563,309bps in 2025.
  • Mereo BioPharma Group's EBITDA Margin (Quarterly) stood at -500.60% in 2023, then spiked by 444,487bps to 3,944.27% in 2024, then crashed by 563,309bps to -3,415.81% in 2025.
  • Its EBITDA Margin was -3,415.81% in Q3 2025, compared to 33,204.17% in Q2 2025 and 5,182.22% in Q1 2025.